Phase-2 trial of indigenously developed Covaxin begins in Nagpur

New Delhi: The phase-2 clinical trial of indigenously developed Covaxin for Covid-19 began in Nagpur today. Hyderabad based Bharat Biotech has developed this vaccine for coronavirus.

Nagpur based Gillurkar hospital has started the second round of trial of indigenously made Covaxin. 55 volunteers had undergone clinical trial in the first phase a few days ago.

None of them had reported any kind of complication after they were given the first shots of the vaccine. The hospital has achieved a unique feat as it ranks second in conducting clinical trials of this vaccine developed by the Hyderabad based company.

Director of Gillurkar hospital, Chandrashekhar Gillurkar said that those volunteers who were given first dose of the vaccine, their blood samples will be collected and sent to examine the antibodies present in them.

Subsequently, the vaccine trial will be done after a gap of 28 days, 42 days, 104 days and 194th day. After each dose, the blood samples will be collected to check the growth in antibodies.